)
According to a statement by Alchemia Ltd, an Australian pharmaceutical company which has marketing tieup with the city-based drug maker, Dr Reddy’s is expected to file for approval in up to four additional territories in 2014.
"The company (Alchemia) also expects Dr Reddy's to launch Fondaparinux in Canada in the coming months. Dr Reddy's has informed Alchemia that it has already received a notice of compliance from Health Canada for 2.5 mg, 5 mg, 7.5 mg and 10 mg strengths, which are sufficient to address the whole Fondaparinux market in Canada," the ASX-listed company said.
“In addition, the company is pleased to note that Dr Reddy's has filed generic applications for Fondaparinux with local regulatory authorities in two additional emerging markets,” the statement said.
A DRL spokesperson said they will not be able to reveal the time of launch until everything is finalised.
